Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.03
Percentage change -2.44	%

Peers: PFE AMGN MRK BNTX GSK BMY NKTR NVAX TGTX ONCY

Index	-	P/E	-	EPS (ttm)	-1.17	Insider Own	3.78%	Shs Outstand	44.59M	Perf Week	-0.83%
Market Cap	53.51M	Forward P/E	-	EPS next Y	-1.22	Insider Trans	1.82%	Shs Float	42.90M	Perf Month	-22.58%
Income	-40.56M	PEG	-	EPS next Q	-0.28	Inst Own	9.52%	Short Float	9.03%	Perf Quarter	-44.19%
Sales	0.00M	P/S	-	EPS this Y	20.14%	Inst Trans	-1.62%	Short Ratio	6.03	Perf Half Y	-60.00%
Book/sh	0.60	P/B	2.01	EPS next Y	-10.21%	ROA	-73.98%	Short Interest	3.87M	Perf Year	-80.13%
Cash/sh	1.12	P/C	1.08	EPS next 5Y	3.39%	ROE	-174.49%	52W Range	1.13 - 6.00	Perf YTD	-26.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	42.97%	ROI	-118.90%	52W High	-80.00%	Beta	1.48
Dividend TTM	-	Quick Ratio	2.84	Sales past 5Y	0.00%	Gross Margin	-	52W Low	6.19%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	2.84	EPS Y/Y TTM	31.68%	Oper. Margin	-	RSI (14)	40.27	Volatility	12.34% 15.29%
Employees	25	Debt/Eq	1.12	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	10.83
Option/Short	Yes / Yes	LT Debt/Eq	0.55	EPS Q/Q	16.98%	Payout	-	Rel Volume	0.89	Prev Close	1.23
Sales Surprise	-	EPS Surprise	2.26%	Sales Q/Q	-	Earnings	Nov 14 BMO	Avg Volume	641.87K	Price	1.20
SMA20	-11.67%	SMA50	-19.41%	SMA200	-54.59%	Trades		Volume	573,920	Change	-2.44%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-01-22	Initiated	B. Riley Securities	Buy	$10
Jun-28-21	Initiated	Cantor Fitzgerald	Overweight	$25
Nov-10-20	Upgrade	H.C. Wainwright	Neutral → Buy	$6
May-27-20	Initiated	Alliance Global Partners	Buy	$4
Mar-09-20	Initiated	Noble Capital Markets	Outperform	$5.45
Oct-24-19	Initiated	Chardan Capital Markets	Buy	$10

Today 12:49PM	PDS Biotechnology commences trial for head and neck squamous cell carcinoma (Clinical Trials Arena)
Mar-07-25 08:45AM	PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune HPV in HPV16-Positive Head and Neck Cancer (GlobeNewswire) -8.21%
Feb-27-25 08:00AM	PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -11.69%
Feb-26-25 08:00AM	PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology (GlobeNewswire) +22.22%
Feb-24-25 08:00AM	PDS Biotech Announces Circulating Tumor DNA Results for Versamune HPV in IMMUNOCERV Trial Published in Clinical Cancer Research (GlobeNewswire) -5.22%
08:00AM	Loading…
Feb-20-25 08:00AM	PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025 (GlobeNewswire)
Feb-05-25 08:00AM	PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Dec-06-24 08:00AM	PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.50%
Dec-03-24 08:00AM	PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET (GlobeNewswire)
Nov-20-24 09:35AM	Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround (Zacks)
Nov-15-24 02:08AM	PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com) -10.67%
Nov-14-24 08:07AM	PDS Biotechnology: Q3 Earnings Snapshot (Associated Press Finance) -18.33%
08:00AM	PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-06-24 08:00AM	PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time (GlobeNewswire)
Oct-22-24 12:00PM	PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
08:00AM	Loading…
08:00AM	PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine (GlobeNewswire)
Oct-02-24 08:00AM	PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune HPV and Chemoradiation (GlobeNewswire) +12.60%
Sep-16-24 07:00AM	PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024 (GlobeNewswire)
Sep-09-24 08:00AM	PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024 (GlobeNewswire)
Sep-03-24 08:00AM	PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.63%
Aug-13-24 08:09AM	PDS Biotechnology: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-08-24 08:00AM	PDS Biotech Announces Abstract Accepted for Oral Presentation at 2024 ASTRO Annual Meeting (GlobeNewswire)
Aug-07-24 08:00AM	PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024 (GlobeNewswire)
Aug-05-24 08:00AM	PDS Biotech Announces Abstract Accepted for Presentation at ESMO Congress 2024 (GlobeNewswire)
Aug-01-24 07:45AM	PDS Biotech Aligns with FDA on Phase 3 Trial in HPV16-Positive First-Line Recurrent or Metastatic Head and Neck Cancer (GlobeNewswire) -9.27%
Jul-31-24 04:01PM	PDS Biotech to Host Clinical Program Update Conference Call on August 1, 2024, at 8 a.m. Eastern Time (GlobeNewswire)
Jul-29-24 08:00AM	PDS Biotech to Participate at BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-12-24 08:00AM	PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck Cancer (GlobeNewswire) +6.16%
May-28-24 01:24PM	Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults (PR Newswire)
12:52PM	Loading…
May-15-24 12:52PM	PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q1 2024 (InvestorPlace)
08:08AM	PDS Biotechnology: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-10-24 05:49AM	PDS Biotechnology Says Head, Neck Cancer Therapy Met Main Goal in Mid-Stage Study (MT Newswires) -8.36%
May-09-24 05:46PM	PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer (GlobeNewswire)
08:00AM	PDS Biotech to Participate in Upcoming May 2024 Investor Conferences (GlobeNewswire)
May-07-24 08:00AM	PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024 (GlobeNewswire)
May-03-24 08:00AM	PDS Biotechnology Announces Details of Virtual KOL Event (GlobeNewswire)
May-02-24 08:00AM	PDS Biotech Appoints Stephan Toutain as Chief Operating Officer (GlobeNewswire)
Apr-23-24 08:00AM	PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune HPV in Combination with KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer (GlobeNewswire) +7.02%
Mar-28-24 10:24AM	PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-27-24 11:33PM	Q4 2023 PDS Biotechnology Corp Earnings Call (Thomson Reuters StreetEvents) -14.06%
11:52AM	PDSB Stock Earnings: PDS Biotechnology Beats EPS for Q4 2023 (InvestorPlace)
08:51AM	PDS Biotechnology Corp (PDSB) Reports Full Year 2023 Financial Results and Clinical Strategy Update (GuruFocus.com)
07:30AM	PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results (GlobeNewswire)
Mar-20-24 08:00AM	PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results (GlobeNewswire)
Mar-13-24 10:55AM	The 3 Most Undervalued Biotech Stocks to Buy in March 2024 (InvestorPlace)
08:00AM	PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune (GlobeNewswire)
Jan-22-24 04:45PM	PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer (GlobeNewswire) +12.03%
Jan-16-24 08:00AM	PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference (GlobeNewswire) -5.44%
Jan-02-24 12:00PM	All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy (Zacks)
Dec-04-23 04:50PM	PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-28-23 07:30AM	PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer (GlobeNewswire) -9.66%
Nov-15-23 01:03PM	PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 12:19PM	PDS Biotechnology Corp (PDSB) Reports Increased Net Loss in Q3 2023 Amid Advancements in ... (GuruFocus.com) +18.55%
07:42AM	PDS Biotechnology: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-09-23 08:00AM	PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Na ve Patients at 36 Months (GlobeNewswire) +5.36%
Nov-07-23 08:00AM	PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-23-23 08:00AM	PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO (GlobeNewswire)
Oct-11-23 08:00AM	PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer (GlobeNewswire)
Oct-03-23 07:00AM	PDS Biotech Announces Interim 24-Month Survival Rate of 74% in Immune Checkpoint Inhibitor Na ve Head and Neck Cancer Patients Treated with PDS0101 in Combination with KEYTRUDA (pembrolizumab) (GlobeNewswire) -14.47%
Oct-02-23 08:00AM	PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA) (GlobeNewswire) -6.93%
Sep-26-23 08:00AM	PDS Biotech to Present at the LD Micro Main Event XVI (GlobeNewswire)
Sep-25-23 08:00AM	PDS Biotech Reschedules Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 (GlobeNewswire)
Sep-20-23 04:05PM	PDS Biotech to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
08:00AM	PDS Biotech Announces PDS0202 Elicits Active Neutralization of Multiple Influenza Strains in Preclinical Studies (GlobeNewswire)
Sep-13-23 08:00AM	PDS Biotech to Host Key Opinion Leader Roundtable Addressing Current and Future Treatments for Recurrent/Metastatic HPV-Positive HNSCC and the Potential Application of PDS0101 on September 27, 2023 (GlobeNewswire)
Sep-06-23 04:05PM	PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
08:00AM	PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference (GlobeNewswire)
Aug-29-23 11:32AM	PDS Biotech's (PDSB) Shares Up 12% in a Month: Here's Why (Zacks) -6.56%
Aug-16-23 08:00AM	PDS Biotech Announces Data from IMMUNOCERV Phase 2 Trial Investigating PDS0101 and Chemoradiotherapy in Cervical Cancer to be Featured in Oral Presentation at the ASTRO 2023 Annual Meeting (GlobeNewswire) +5.95%
Aug-14-23 11:42PM	Q2 2023 PDS Biotechnology Corp Earnings Call (Thomson Reuters StreetEvents) +9.90% +10.32%
07:37AM	PDS Biotechnology: Q2 Earnings Snapshot (AP Finance)
07:30AM	PDS Biotech Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial (GlobeNewswire)
Aug-07-23 08:00AM	PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-02-23 08:00AM	PDS Biotech to Present at BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jul-25-23 08:00AM	PDS Biotech to Present Immune Response Data from Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients at ESMO Congress 2023 (GlobeNewswire)
Jul-17-23 08:00AM	PDS Biotech Announces Acceptance of Abstract on Combination of PDS0301 with Docetaxel in Metastatic Prostate Cancer for Oral Presentation by the National Cancer Institute at Cytokines 2023 (GlobeNewswire) +7.60%
Jul-11-23 08:00AM	PDS Biotech Strengthens Intellectual Property Portfolio Governing A Combination of Versamune® and PDS0301 (GlobeNewswire)
Jun-30-23 04:05PM	PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-20-23 08:00AM	PDS Biotech to be Added to Russell 2000® and Russell 3000® Indexes Effective June 26, 2023 (GlobeNewswire)
Jun-14-23 08:00AM	PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer (GlobeNewswire) -9.88%
Jun-05-23 02:52PM	PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET (GlobeNewswire) -30.68%
May-25-23 05:00PM	PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients (GlobeNewswire) -6.99% +27.38%
May-18-23 08:00AM	PDS Biotech Completes Enrollment in Immune Checkpoint Inhibitor Naïve Arm of VERSATILE-002 Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer (GlobeNewswire)
May-17-23 01:54PM	PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-15-23 09:46PM	Q1 2023 PDS Biotechnology Corp Earnings Call (Thomson Reuters StreetEvents) +7.44%
07:40AM	PDS Biotechnology: Q1 Earnings Snapshot (AP Finance)
07:30AM	PDS Biotech Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 08:00AM	PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 08:00AM	PDS Biotech to Present Updated Data at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting Highlighting Combination of PDS0101 and KEYTRUDA® (pembrolizumab) in Head and Neck Cancer Patients (GlobeNewswire)
Apr-24-23 08:00AM	PDS Biotech Receives $1.4 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Development Program (GlobeNewswire)
Apr-12-23 08:00AM	PDS Biotech to Host Interleukin 12 (IL-12) Immunocytokine-Focused KOL Roundtable on April 21, 2023 (GlobeNewswire)
Apr-03-23 08:00AM	PDS Biotech Supports Oral, Head & Neck Cancer Awareness Month During April and Oral, Head & Neck Cancer Awareness Week from April 16-22, 2023 (GlobeNewswire)
Mar-30-23 08:28AM	PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2022 Earnings Call Transcript (Insider Monkey)
08:00AM	PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023 (GlobeNewswire)
Mar-29-23 07:30AM	PDS Biotech to Participate in Cantors Future of Oncology Virtual Symposium (GlobeNewswire)
Mar-28-23 07:30AM	PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2022 Financial Results (GlobeNewswire)

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its product, PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Freitag Gregory Gene	Director	Feb 28 '25	Buy	1.66	15,060	25,000	61,213	Mar 03 04:45 PM
Glover Stephen C.	Director	Feb 28 '25	Buy	1.66	15,061	25,001	78,851	Mar 03 04:45 PM

Open in Screener

AXGN

Axogen Inc

Mar 10 • 04:00PM ET

17.17

Dollar change -0.56
Percentage change -3.16	%

Healthcare • Medical Devices • USA • NASD

Peers: IART BAX SYK ZBH MDT JNJ GMED EW PODD HOLX

| Held by: VTI IWM VXF IWO IHI FESM SCHA VTWO DFAS IWC

Index	RUT	P/E	-	EPS (ttm)	-0.23	Insider Own	5.55%	Shs Outstand	44.15M	Perf Week	-10.99%
Market Cap	761.39M	Forward P/E	34.03	EPS next Y	0.50	Insider Trans	-0.20%	Shs Float	41.83M	Perf Month	-6.33%
Income	-9.96M	PEG	-	EPS next Q	0.01	Inst Own	81.67%	Short Float	4.43%	Perf Quarter	15.78%
Sales	187.34M	P/S	4.06	EPS this Y	115.62%	Inst Trans	-1.71%	Short Ratio	3.69	Perf Half Y	29.58%
Book/sh	2.35	P/B	7.30	EPS next Y	79.99%	ROA	-4.98%	Short Interest	1.85M	Perf Year	89.51%
Cash/sh	0.89	P/C	19.29	EPS next 5Y	77.74%	ROE	-9.99%	52W Range	5.55 - 21.00	Perf YTD	4.19%
Dividend Est.	-	P/FCF	532.44	EPS past 5Y	21.24%	ROI	-5.84%	52W High	-18.24%	Beta	1.01
Dividend TTM	-	Quick Ratio	2.16	Sales past 5Y	12.00%	Gross Margin	75.79%	52W Low	209.37%	ATR (14)	1.14
Dividend Ex-Date	Jan 27, 2010	Current Ratio	3.24	EPS Y/Y TTM	54.69%	Oper. Margin	-1.80%	RSI (14)	40.96	Volatility	5.91% 6.50%
Employees	452	Debt/Eq	0.66	Sales Y/Y TTM	17.81%	Profit Margin	-5.32%	Recom	1.14	Target Price	25.57
Option/Short	Yes / Yes	LT Debt/Eq	0.64	EPS Q/Q	110.40%	Payout	-	Rel Volume	1.51	Prev Close	17.73
Sales Surprise	1.72%	EPS Surprise	96.63%	Sales Q/Q	15.10%	Earnings	Mar 04 BMO	Avg Volume	502.96K	Price	17.17
SMA20	-6.75%	SMA50	-4.04%	SMA200	31.30%	Trades		Volume	760,398	Change	-3.16%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-01-24	Initiated	Raymond James	Outperform	$13
Nov-11-22	Resumed	Jefferies	Buy	$15
May-09-22	Upgrade	Canaccord Genuity	Hold → Buy	$10 → $15
Mar-11-22	Resumed	Cantor Fitzgerald	Overweight	$21
Oct-23-20	Initiated	Guggenheim	Buy	$24
Jun-16-20	Resumed	Cantor Fitzgerald	Overweight	$16
May-07-20	Downgrade	Canaccord Genuity	Buy → Hold	$12
Apr-02-20	Downgrade	BTIG Research	Buy → Neutral
Aug-07-19	Downgrade	William Blair	Outperform → Mkt Perform
Jul-12-19	Initiated	Canaccord Genuity	Buy	$32
Mar-02-18	Reiterated	Lake Street	Buy	$26 → $38
Jan-05-18	Resumed	Cantor Fitzgerald	Overweight
Nov-30-17	Initiated	Jefferies	Buy	$35
Nov-21-17	Reiterated	Lake Street	Buy	$22 → $26
Jul-31-17	Initiated	Leerink Partners	Outperform	$22
Jun-30-17	Initiated	Cantor Fitzgerald	Overweight	$18
Mar-06-17	Initiated	ROTH Capital	Buy	$14.50
Nov-22-16	Upgrade	Lake Street	Hold → Buy	$9 → $11
Nov-07-16	Reiterated	Wedbush	Outperform	$10 → $12
Nov-03-16	Downgrade	Lake Street	Buy → Hold	$9

Show Previous Ratings

Mar-04-25 03:04PM	Alcon Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
Feb-26-25 02:03AM	Axogen Inc (AXGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Market ... (GuruFocus.com)
12:27AM	Q4 2024 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-25-25 07:41AM	AxoGen: Q4 Earnings Snapshot (Associated Press Finance) +11.66%
07:10AM	Axogen, Inc. To Host Analyst & Investor Day on March 4th (GlobeNewswire)
07:00AM	Loading…
07:00AM	Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results (GlobeNewswire)
Feb-11-25 04:58PM	Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025 (GlobeNewswire)
Feb-03-25 08:00AM	Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-13-25 09:35AM	AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out? (Zacks)
05:05AM	AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last? (Zacks)
Jan-10-25 05:00PM	Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +18.21%
08:00AM	Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024 (GlobeNewswire)
Dec-24-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks) -5.41%
Dec-19-24 09:40AM	Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-28-24 12:00PM	All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy (Zacks)
09:55AM	Loading…
Nov-25-24 09:55AM	How Much Upside is Left in AxoGen (AXGN)? Wall Street Analysts Think 31.18% (Zacks)
Nov-08-24 07:35AM	AxoGen Reports Strong Q3 2024 Revenue Growth (TipRanks)
02:08AM	Axogen Inc (AXGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
Nov-07-24 07:48AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance) -13.44%
07:00AM	Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update (GlobeNewswire)
Oct-24-24 07:00AM	Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024 (GlobeNewswire)
Oct-14-24 07:21AM	AxoGen (AXGN) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Oct-09-24 05:30PM	Axogen Inc (AXGN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... (GuruFocus.com)
Sep-12-24 01:30AM	ArrowMark Colorado Holdings LLC Reduces Stake in Axogen Inc (GuruFocus.com)
Sep-06-24 07:00AM	Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft (GlobeNewswire)
Sep-04-24 09:15AM	AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-03-24 07:00AM	Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4) (GlobeNewswire)
Aug-30-24 12:00PM	What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now? (Zacks)
Aug-23-24 09:55AM	Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High? (Zacks)
Aug-19-24 09:15AM	AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run? (Zacks)
04:18PM	Loading…
Aug-13-24 04:18PM	CytoSorbents Appoints Peter J. Mariani Chief Financial Officer (GlobeNewswire)
Aug-09-24 12:56AM	Axogen names ex-Abbott exec Michael Dale as CEO (MedTech Dive)
Aug-08-24 08:20AM	AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates (Zacks) +35.10%
07:19AM	AxoGen: Q2 Earnings Snapshot (Associated Press Finance)
07:05AM	Axogen, Inc. Announces New Leadership Appointments (GlobeNewswire)
07:00AM	Axogen, Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 10:01AM	AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -7.06%
Jul-23-24 07:00AM	Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024 (GlobeNewswire)
Jul-12-24 08:37AM	AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock? (Zacks)
Jul-01-24 07:00AM	Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.49%
Jun-25-24 12:52PM	AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection (Zacks)
Jun-24-24 07:00AM	Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix (GlobeNewswire)
Jun-12-24 04:56AM	Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength? (Zacks) +9.21%
May-28-24 04:30PM	Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia (GlobeNewswire) +5.90%
May-17-24 12:29PM	AxoGen (AXGN) Initiates BLA Submission for Avance Nerve Graft (Zacks)
May-16-24 02:56PM	AxoGen Initiates Rolling Submission to FDA For Avance Nerve Graft (MT Newswires)
07:00AM	Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft (GlobeNewswire)
May-14-24 07:00AM	Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference (GlobeNewswire)
May-06-24 10:31AM	AxoGen, Inc. (NASDAQ:AXGN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-03-24 03:02AM	Axogen Inc (AXGN) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst Challenges (GuruFocus.com)
May-02-24 11:57AM	AXGN Stock Earnings: Axogen Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -10.37%
08:15AM	AxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:14AM	AxoGen: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-29-24 04:50PM	Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix (GlobeNewswire)
Apr-16-24 07:00AM	Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024 (GlobeNewswire)
Mar-08-24 11:55PM	Director Gregory Freitag Sells 25,000 Shares of Axogen Inc (AXGN) (GuruFocus.com)
Mar-06-24 08:20AM	AxoGen, Inc. (NASDAQ:AXGN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-05-24 09:27PM	Q4 2023 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents) -15.11%
11:53AM	AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
07:38AM	AxoGen: Q4 Earnings Snapshot (Associated Press Finance)
07:31AM	Axogen Inc (AXGN) Reports Growth in Revenue and Reduction in Net Loss for Q4 and Full-Year 2023 (GuruFocus.com)
07:00AM	Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results (GlobeNewswire)
Feb-28-24 08:50AM	AxoGen (AXGN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Feb-26-24 09:15AM	AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue? (Zacks)
Feb-13-24 04:30PM	Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024 (GlobeNewswire)
Feb-12-24 08:50AM	Here's Why Momentum in AxoGen (AXGN) Should Keep going (Zacks)
Feb-06-24 09:40AM	Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-02-24 04:15PM	Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-26-24 08:50AM	Here's What Could Help AxoGen (AXGN) Maintain Its Recent Price Strength (Zacks)
Jan-18-24 05:00PM	Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap (GlobeNewswire) +7.86%
Jan-04-24 04:45PM	Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023 (GlobeNewswire) +26.67%
04:40PM	Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025 (GlobeNewswire)
04:35PM	Axogen Announces Promotions on Research and Development Team (GlobeNewswire)
Dec-26-23 04:15PM	Axogen, Inc. Appoints Kathy Weiler to its Board of Directors (GlobeNewswire)
Dec-06-23 07:00AM	Axogen Announces Transition of Finance Team Leadership (GlobeNewswire) +5.19%
Dec-01-23 05:00PM	Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.04%
Nov-20-23 07:00AM	Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-08-23 09:41AM	AxoGen, Inc. (NASDAQ:AXGN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 11:01PM	Q3 2023 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents) +36.90%
08:04AM	Axogen Inc (AXGN) Reports 12% Revenue Growth in Q3 2023 (GuruFocus.com)
07:15AM	AxoGen: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Axogen, Inc. Reports 2023 Third Quarter Financial Results (GlobeNewswire)
Nov-02-23 10:00AM	Dynatronics Corporation (DYNT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) +5.26%
Oct-31-23 10:01AM	AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-18-23 07:00AM	Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023 (GlobeNewswire)
Oct-16-23 10:23AM	Wayfair upgraded, JD.com downgraded: Wall Street's top analyst calls (The Fly) +5.28%
Sep-28-23 08:21AM	AxoGen (AXGN) Moves 6.8% Higher: Will This Strength Last? (Zacks)
Sep-05-23 07:00AM	Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector (GlobeNewswire)
Aug-31-23 07:00AM	Axogen to Participate at Upcoming Investor Conferences (GlobeNewswire)
Aug-21-23 07:00AM	Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio (GlobeNewswire)
Aug-10-23 03:03PM	ArrowMark Colorado Holdings LLC Boosts Stake in Axogen Inc (GuruFocus.com) -6.51%
12:05PM	AxoGen, Inc. (NASDAQ:AXGN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-08-23 10:59AM	The past five years for AxoGen (NASDAQ:AXGN) investors has not been profitable (Simply Wall St.) -19.44%
05:57AM	Q2 2023 AxoGen Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 05:25PM	AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:18PM	AxoGen: Q2 Earnings Snapshot (AP Finance)
04:01PM	Axogen, Inc. Reports 2023 Second Quarter Financial Results (GlobeNewswire)
Aug-03-23 05:55PM	Artivion (AORT) Q2 Earnings and Revenues Top Estimates (Zacks)
Jul-27-23 07:00AM	Axogen to Participate at Canaccord Genuitys 43rd Annual Growth Conference (GlobeNewswire) -6.83%

Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Began Marc A	EVP & General Counsel	Mar 01 '25	Option Exercise	0.00	22,500	0	24,186	Mar 05 06:24 PM
Wendell Amy McBride	Director	Mar 03 '25	Sale	20.02	5,000	100,100	97,899	Mar 05 06:20 PM
DeVinney Erick Wayne	Chief Innovation Officer	Feb 28 '25	Option Exercise	0.00	24,799	0	209,301	Mar 04 07:22 PM
AMY MCBRIDE-WENDELL	Director	Mar 03 '25	Proposed Sale	20.01	5,000	100,050		Mar 03 04:16 PM
Kemp Jens	Chief Marketing Officer	Feb 22 '25	Option Exercise	0.00	2,500	0	2,500	Feb 26 04:25 PM
Zaderej Karen L.	SENIOR ADVISOR	Jan 21 '25	Proposed Sale	18.41	220,000	4,050,000		Jan 21 01:20 PM
Zaderej Karen L.	SENIOR ADVISOR	Jan 14 '25	Proposed Sale	18.00	100,000	1,800,000		Jan 14 01:24 PM
Zaderej Karen L.	SENIOR ADVISOR	Nov 07 '24	Proposed Sale	12.71	70,000	890,000		Nov 07 10:52 AM
Zaderej Karen L.	SENIOR ADVISOR	Sep 05 '24	Proposed Sale	13.00	150,000	1,950,000		Sep 05 04:33 PM
JOHNSON JOHN	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	29,016	Sep 04 09:13 PM
NEELS GUIDO J	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	90,816	Sep 04 09:11 PM
Levine Alan M	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	40,816	Sep 04 08:58 PM
Burke William P. Mr.	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	28,557	Sep 04 08:52 PM
THOMAS PAUL	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	32,052	Sep 04 08:33 PM
TYNDALL JOSEPH A.	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	22,557	Sep 04 07:52 PM
Wendell Amy McBride	Director	Sep 01 '24	Option Exercise	0.00	11,904	0	102,899	Sep 04 05:18 PM
Donovan Michael Patrick	Officer	Aug 21 '24	Proposed Sale	12.42	28,003	347,810		Aug 21 04:31 PM
GREG FREITAG	Director	Aug 13 '24	Proposed Sale	11.17	15,000	167,520		Aug 13 05:00 PM
Zaderej Karen L.	SENIOR ADVISOR	Aug 12 '24	Proposed Sale	10.00	200,000	2,000,000		Aug 12 10:59 AM
Freitag Gregory Gene	Director	Jun 04 '24	Option Exercise	0.00	11,904	0	283,498	Jun 06 04:49 PM
Zaderej Karen L.	CEO	Mar 16 '24	Option Exercise	0.00	110,322	0	1,157,593	Mar 25 09:43 PM
Zaderej Karen L.	CEO	Mar 21 '24	Sale	7.68	39,280	301,670	1,124,565	Mar 25 09:43 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 16 '24	Option Exercise	0.00	18,675	0	180,615	Mar 25 09:40 PM
DeVinney Erick Wayne	Chief Innovation Officer	Mar 21 '24	Sale	7.68	4,578	35,159	165,661	Mar 25 09:40 PM
Scopelianos Angelo	Chief R&D Officer	Mar 21 '24	Option Exercise	0.00	2,500	0	58,604	Mar 25 09:37 PM
Scopelianos Angelo	Chief R&D Officer	Mar 16 '24	Option Exercise	0.00	25,406	0	58,250	Mar 25 09:37 PM
Scopelianos Angelo	Chief R&D Officer	Mar 21 '24	Sale	7.68	6,881	52,846	52,999	Mar 25 09:37 PM
Donovan Michael Patrick	VP Operations	Mar 16 '24	Option Exercise	0.00	24,575	0	58,846	Mar 25 09:22 PM
Donovan Michael Patrick	VP Operations	Mar 21 '24	Sale	7.68	6,033	46,333	37,992	Mar 25 09:22 PM

PDSB

PDS Biotechnology Corporation

AXGN

Axogen Inc

Upgrade your FINVIZ experience